Tatva Chintan Pharma Chem Limited was incorporated in 1996 and it is a manufacturer of a diverse portfolio of structure Directing Agents, Phase Transfer Catalysts, electrolyte salts for batteries, and Pharmaceutical and Agrochemical Intermediates and other Speciality chemicals
Accumulate slowly - Even though results are not impressive in Q4 2023.
Elevated PE - Negative
Q4 - Results Negative
Company comments for future :
Accumulate slowly - Even though results are not impressive in Q4 2023.
Elevated PE - Negative
Q4 - Results Negative
Company comments for future :
- Future Plans and Strategies:
Expect 20-30% revenue growth in FY24, potential for 40-50% growth if pricing remains the same
Launching new products on commercial scale in FY24
Anticipate rebound in demand for SDAs
Capex of INR16-17 crores expected for new Agro intermediate product, total capex of INR30-35 crores for the year
Operating leverage to increase in FY25 due to new plant operations and continuous flow chemistry
Revenue growth guidance for FY24 is 20-30%
Electrolyte sales expected to have nearly 100% growth in FY24
Flame retardant revenue expected to be INR40-50 crores this year and INR200 crores next year
Tatva Chintan committed to delivering and improving the market for their products going forward.
Transaction en cours:
T1 1700 - Done
Transaction en cours:
1750 and above
Transaction en cours
Transaction en cours:
T2 Done - Trail SL